Blueprint Medicines Corporation (BPMC - Free Report) incurred a loss of $2.11 per share in the first quarter of 2020, narrower than the Zacks Consensus Estimate of a loss of $2.15 but wider than the year-ago quarter’s loss of $1.98.
Total revenues of $6.2 million were above the Zacks Consensus Estimate of $5 million. The top line also grew significantly year over year, mainly owing to increased collaboration revenues and product sales.
In January 2020, Blueprint Medicines’ lead product Ayvakit (avapritinib) was approved by the FDA for treating unresectable or metastatic gastrointestinal stromal tumor (GIST), harboring a PDGFRA exon 18 mutation including PDGFRA D842V mutations in adults.
Following this nod, Ayvakit became the first precision therapy to have won the FDA nod for treating genomically-defined patients with GIST, a rare form of cancer. Ayvakit in its first partial quarter since its launch in January this year generated sales worth $3.5 million. The drug is also under review in Europe with a decision pending in the third quarter 2020. A potential approval should boost Ayvakit’s sales in the quarters ahead.
Meanwhile, first-quarter collaboration revenues of $2.7 million rose significantly year over year. This portion of the top line is derived from the company’s partnership with Roche (RHHBY - Free Report) and CStone Pharmaceuticals, which was formed to develop and commercialize its pipeline candidates.
Shares of Blueprint Medicines have declined 26.3% so far this year against the industry’s increase of 3.7%.
Quarter in Detail
Research and development expenses were $84.1 million, up 13.2% from the year-ago figure, mainly due to higher spending associated with the lead candidates’ development and increased personnel costs.
General and administrative expenses were $35.7 million, up 115.1% year over year on account of higher personnel fees, infrastructure costs and other commercial costs.
Blueprint Medicines had cash, cash equivalents and marketable securities worth $750.4 million as of Mar 31, 2020, higher than the sequential quarter’s $548 million.
Ayvakit & Other Pipeline Updates
In April 2020, Blueprint Medicines announced that the phase III VOYAGER study evaluating the safety and efficacy of Ayvakit compared to Bayer’s (BAYRY - Free Report) Stivarga (regorafenib) in patients with third- and fourth-line GIST, did not meet its primary endpoint of improvement in progression-free survival (PFS) for Ayvakit versus Stivarga. Based on the top-line data from the VOYAGER study, the company plans to discontinue further development of Ayvakit for GIST indications other than PDGFRA exon 18 mutant GIST.
Notably, Ayvakit is also being studied for advanced, indolent and smoldering forms of systemic mastocytosis (SM).
This apart, Blueprint Medicines submitted an NDA to the FDA and marketing applications in the EU for its precision therapy, pralsetinib, to address RET fusion-positive non-small-cell lung carcinoma (NSCLC). Additionally, pralsetinib is being studied for the treatment of RET-mutant medullary thyroid carcinoma (MTC). The company is further on track to file an NDA for the MTC indication in the second quarter of 2020 under the FDA's Real-Time Oncology Review pilot program.
Blueprint Medicines Corporation Price, Consensus and EPS Surprise
Zacks Rank & Key Pick
Blueprint Medicines currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the healthcare sector is Menlo Therapeutics Inc. (MNLO - Free Report) , sporting a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Menlo Therapeutics’ loss per share estimates have narrowed 38.2% for 2020 and 66.7% for 2021 over the past 60 days.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>